<i>Pseudomonas aeruginosa</i>: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors.
Jurado-Martín I, Sainz-Mejías M, McClean S. · 2021
Read <i>Pseudomonas aeruginosa</i>: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors. by Jurado-Martín I, Sainz-Mejías M, McClean S. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8003266.txt.
Introduction
Jurado-Martín and co-authors present a review of Pseudomonas aeruginosa, a bold germ with a flexible set of weapons. The germ is a leading cause of harm and death in people with cystic fibrosis. Its skill at adapting lets it settle into chronic infections that resist clearance. That skill rests on the many virulence factors it can call on. It tailors its attack to each stress it meets in the body.
The review describes the main weapons in turn. It then follows the changes the germ makes to persist in harsh places such as the cystic fibrosis airway. Its genome is very large, at 5 to 7 MB. That size helps explain its range, and genome studies have traced its evolution inside hosts. The authors argue that a deep grasp of these tools is the key to new therapies and vaccines.
Catalog record
| CREATOR | Jurado-Martín I, Sainz-Mejías M, McClean S. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 162 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Pseudomonas aeruginosa: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors By Irene Jurado-Martín, Maite Sainz-Mejías, Siobhán McClean, Jorge H Leitão Published in: International Journal of Molecular Sciences DOI: 10.3390/ijms22063128 ABSTRACT Abstract Pseudomonas aeruginosa is a dominant pathogen in people with cystic fibrosis (CF) contributing to morbidity and mortality. Its tremendous ability to adapt greatly facilitates its capacity to cause chronic infections. The adaptability and flexibility of the pathogen are afforded by the extensive number of virulence factors it has at its disposal, providing P. aeruginosa with the facility to tailor its response against the different stressors in the environment. A deep understanding of these virulence mechanisms is crucial for the design of therapeutic strategies and vaccines against this multi-resistant pathogen. Therefore, this review describes the main virulence factors of P. aeruginosa and the adaptations it undergoes to persist in hostile environments such as the CF respiratory tract. The very large P. aeruginosa genome (5 to 7 MB) contributes considerably to its adaptive capacity; consequently, genomic studies have provided significant insights into elucidating P. aeruginosa evolution and its interactions with the host throughout the course of infection. Keywords: Pseudomonas aeruginosa, virulence factors, adaptation, cystic fibrosis, diversity, genomics, lung environment 1. INTRODUCTION Pseudomonas aeruginosa is a significant cause of healthcare-associated infections, being particularly problematic in intensive care units. Its infections are associated with high morbidity and mortality in many groups, including individuals with healthcare-associated pneumonia, chronic obstructive pulmonary disease (COPD), or cystic fibrosis (CF) [1,2,3,4,5,6,7,8]. It is included in the “critical” category of the World Health Organisation’s (WHO) priority list of bacterial pathogens for which research and development of new antibiotics are urgently needed [9,10]. As a versatile opportunistic pathogen, P. aeruginosa is capable of causing both acute and chronic infections. Its pathogenic profile stems from the large and variable arsenal of virulence factors and antibiotic resistance determinants harboured in P. aeruginosa’s genome, which confer remarkable metabolic flexibility and the ability to adapt to multiple conditions, including the host immune response [1,11,12,13]. P. aeruginosa–host interactions are still poorly understood, complicating the development of effective therapies and vaccines. There are still no vaccines available to prevent these infections despite a half century of research effort specifically focussed on this challenge, as recently reviewed [14]. While CF patients are colonised by both P. aeruginosa and Staphylococcus aureus during their childhood, in adulthood, P. aeruginosa predominates, contributing to lung function decline [15,16]. The reasons for P. aeruginosa persistence in CF airway are multifactorial, and the relationship between pathogen traits and host factors that enables the development of chronic infections is highly complex [12]. Nevertheless, it is widely known that the CF environment confers multiple advantages on P. aeruginosa enabling its colonisation of CF airways over other pathogens, such as S. aureus and Klebsiella pneumoniae [15,17]. Consequently, the prevalence of P. aeruginosa in adults with CF ranges from 31% (in Ireland) to 47% (in the US) in recent studies [18]. The genetic and phenotypic properties of persistent P. aeruginosa strains in CF airways differ greatly from those that initiated the infections [19,20], as P. aeruginosa undergoes evolutionary changes in response to the selective forces in CF airways [5]. Understanding the mechanisms of the P. aeruginosa adaptation and evolution during chronic respiratory CF infections could be key to finding of novel therapies against P. aeruginosa infections. This review summarises the multiple virulence factors that provide P. aeruginosa its metabolic flexibility and describes the arsenal of tools that allow P. aeruginosa to persist in the hostile CF environment, highlighting the adaptations by P. aeruginosa throughout the different stages of the infection. The large P. aeruginosa genome (~5 MB to ~7 MB), which comprises multiple genetic regulatory pathways, is also key to understanding the pathoadaptability of this pathogen, especially with current genomic techniques which allow the assessment of differences and similarities across P. aeruginosa populations colonising CF airways. 2. PSEUDOMONAS AERUGINOSA VIRULENCE FACTORS: A WEALTH OF WEAPONRY P. aeruginosa displays a vast repertoire of both cell-associated and extracellular virulence factors that contribute to its pathogenesis, being controlled by incredibly complex, interconnected regulatory circuits and signalling systems, which give this pathogen great plasticity [21,22]. Here, we review the structure and function of the most relevant virulence factors in respiratory infections (Figure 1). [Figure: Schematic presentation of the main virulence factors used by P. aeruginosa during respiratory infections: (a) biofilm formation ability and composition of the extracellular matrix of biofilms (exopolysaccharides, proteins and extracellular DNA); (b) the three main quorum sensing (QS) systems (Las, Rhl and Pqs); (c) flagellins FliC and FliD incorporated within the flagellar structure; (d) pyoverdine (PVD) siderophore as an iron uptake system; (e) type 4 pili (T4P); (f) lipopolysaccharide (LPS) and outer membrane proteins (OMPs); (g) the type III secretion system (T3SS) and its four main effectors; (h) the type VI secretion system (T6SS); (i) the type II secretion system (T2SS) and the compounds it releases to the extracellular milieu: lytic enzymes (lipases, proteases (AprA ad PIV) and elastases (LasA and LasB)), exotoxin A (ETA), and pyocyanin.] 2.1. The Outer Membrane: Lipopolysaccharide and Proteins The outer membrane (OM) of P. aeruginosa has an asymmetric bilayer that limits the entry of harmful compounds, with a phospholipid inner face and a lipopolysaccharide (LPS) outer face, embedded with about 300 proteins (OMPs) that play different roles, most of which remain unknown (Figure 1) [23,24,25,26]. 2.1.1. Lipopolysaccharide Lipopolysaccharide is comprised of three domains: the lipid A, the core region, and the O-antigen or O-polysaccharide (OPS) [27], and various glycoforms which all contribute to its virulence are produced (Section 4) [28]. It constitutes a physical barrier, mediates interactions with host receptors, and causes tissue damage due to its endotoxic activity [29]. LPS stimulates the production of reactive oxygen species (ROS) and gel-forming mucin in airway epithelial cells, which is associated with morbidity and mortality of patients with asthma, COPD, and CF [30,31]. It increases airway epithelial paracellular permeability [32] and induces pulmonary inflammation by stimulating tumour necrosis factor-α (TNF-α), Interleukin (IL)-1, IL-6 and Interferon (IFN)-γ [33]. LPS also contributes to antibiotic resistance and influences the formation of outer membrane vesicles (OMVs) and biofilms [28]. Lipid A is a hydrophobic glycolipid that anchors the other two moieties of LPS into the OM and mediates endotoxicity. It is composed of a diglucosamine biphosphate backbone with O- and N-linked fatty acids and varies among isolates depending on the growth conditions and isolation sources, which has considerable implications for niche adaptation (Section 4) [34]. The acyl chains of the lipid A bind to host cell MD2 receptor, activating the toll-like receptor (TLR)-4 signalling pathway [35]. Both the acyl chains and the phosphates of the lipid A interact with a quinolone of the Pqs quorum sensing (QS) system when it is exported to the OM, inducing membrane curvature, leading to OMV formation [36]. Mutants defective for lipid A synthesis failed to develop biofilms on both biotic and abiotic surfaces and exhibited significantly decreased bacterial attachment to airway epithelial cells, suggesting that LPS may play an indirect role in bacterial adhesion and biofilm formation [37]. O-polysaccharide is a highly variable and immunogenic peripheral long chain of repeating polysaccharides that can be either linear or branched [27]. Two forms of LPS are exposed on bacterial surface, called